Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 1
2019 1
2020 3
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.
Puła B, Pruszczyk K, Pietrusza E, Morawska M, Piszczek W, Kalicińska E, Szeremet A, Tryc-Szponder J, Wąsik-Szczepanek E, Drozd-Sokołowska J, Krzemień H, Rejus A, Gajewska M, Wiśniewski K, Wysocki M, Majeranowski A, Paszkiewicz-Kozik E, Steckiewicz P, Szukalski Ł, Bołkun Ł, Długosz-Danecka M, Giannopoulos K, Jamroziak K, Lech-Marańda E, Hus I. Puła B, et al. Among authors: steckiewicz p. Cancers (Basel). 2022 Jan 22;14(3):558. doi: 10.3390/cancers14030558. Cancers (Basel). 2022. PMID: 35158826 Free PMC article.
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A, Drozd-Sokołowska J, Paszkiewicz-Kozik E, Popławska L, Morawska M, Tryc-Szponder J, Bołkun Ł, Rybka J, Pruszczyk K, Juda A, Majeranowski A, Iskierka-Jażdżewska E, Steckiewicz P, Wdowiak K, Budziszewska B, Jamroziak K, Hus I, Lech-Marańda E, Puła B. Soboń A, et al. Among authors: steckiewicz p. Ann Hematol. 2023 Aug;102(8):2119-2126. doi: 10.1007/s00277-023-05304-4. Epub 2023 Jul 1. Ann Hematol. 2023. PMID: 37392368 Free PMC article.
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM, Górniak P, Pępek M, Szymczyk A, Iskierka-Jażdżewska E, Steckiewicz P, Bluszcz A, Rydzanicz M, Hus M, Płoski R, Makuch-Łasica H, Nowak G, Juszczyński P, Jamroziak K, Stokłosa T, Puła B. Machnicki MM, et al. Among authors: steckiewicz p. Eur J Haematol. 2021 Mar;106(3):320-326. doi: 10.1111/ejh.13550. Epub 2020 Dec 19. Eur J Haematol. 2021. PMID: 33190294
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K. Pula B, et al. Among authors: steckiewicz p. Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403. Anticancer Res. 2020. PMID: 32620653
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Puła B, Długosz-Danecka M, Salomon-Perzyński A, Szymczyk A, Subocz E, Budziszewska BK, Rybka J, Gil L, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Zaucha JM, Osowiecki M, Piszczek W, Steckiewicz P, Szukalski Ł, Hus M, Lech-Marańda E, Jurczak W, Jamroziak K. Puła B, et al. Among authors: steckiewicz p. Adv Med Sci. 2020 Sep;65(2):371-377. doi: 10.1016/j.advms.2020.06.002. Epub 2020 Jul 10. Adv Med Sci. 2020. PMID: 32659728 Free article.
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Iskierka-Jażdżewska E, Hus M, Giannopoulos K, Mądro E, Hołojda J, Piotrowska M, Zaucha JM, Piszczek W, Szeremet A, Wojciechowska M, Steckiewicz P, Knopińska-Posłuszny W, Osowiecki M, Drozd-Sokołowska J, Kumiega B, Kyrcz-Krzemień S, Hałka J, Dudziński M, Wieszczy P, Robak T, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Among authors: steckiewicz p. Leuk Lymphoma. 2017 Oct;58(10):2485-2488. doi: 10.1080/10428194.2017.1292353. Epub 2017 Feb 28. Leuk Lymphoma. 2017. PMID: 28278701 No abstract available.
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E, Puła B, Szeremet A, Hus M, Gołos A, Hołojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Zaucha JM, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Among authors: steckiewicz p. Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911. Adv Clin Exp Med. 2019. PMID: 31199879 Free article.